Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CSL627 versus octocog alfa crossover study in severe hemophilia A
2011-002393-23Phase 3Completed
- Sponsor
- CSL Limited
- Start
- Jul 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of lonoctocog alfa in hemophilia A (2 arms), sponsored by CSL Limited. Primary endpoint: Treatment success rate for bleeding episodes. Started Jul 2011; status: completed.
02
Drugs
lonoctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2011-002393-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002393-23.